Syngene biologics facility to be operational for US, European customers from mid-year
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated